ASP3026 is primarily investigated for its potential in cancer treatment, particularly as an inhibitor of anaplastic lymphoma kinase (ALK). It is studied for its ability to target and inhibit ALK rearrangements, which are often implicated in certain types of non-small cell lung cancer (NSCLC) and other malignancies. By blocking ALK activity, ASP3026 aims to disrupt the signaling pathways that promote tumor growth and survival. Research focuses on its efficacy in patients who have developed resistance to other ALK inhibitors, offering a potential therapeutic option for advanced or refractory cases. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in treating ALK-positive cancers.